Ahmed Mousa, CEO Vicore Pharma receives the SwedenBIO Award 2024 at Grand Hotel in Stockholm on 11th December 2024. Vicore Pharma, the winner of the SwedenBIO Award 2024 is praised for being at the forefront of addressing unmet medical needs in rare diseases and for securing one of Sweden’s largest biotech raises in 2024. Vicore's CEO, Ahmed Mousa, received the award in a prize ceremony during SwedenBIO Summit at Grand Hôtel in Stockholm on 11th December.
Vicore Pharma was founded in the early 2000s based on the design and synthesis of buloxibutid (C21) by Professor Anders Hallberg’s group at Uppsala University. The company is unlocking the potential of a new class of drugs – Angiotensin II Type 2 Receptor Agonists (ATRAGs) – stopping disease progression and restoring function. As a result of the pioneering work with buloxibutid, the first-in-class AT2 receptor agonist (ATRAG), the company now develops a portfolio of products for the treatment of rare lung diseases and following that, a clinical platform with novel compounds for a broad range of indications.
The award was presented to Vicore by Anders Persson, chairman of SwedenBIOs board, with the following motivation: “Vicore is an innovative clinical-stage pharmaceutical company at the forefront of addressing unmet medical needs in rare diseases. This company is redefining therapeutic possibilities with its pioneering lead program targeting idiopathic pulmonary fibrosis (IPF), a devastating lung disease with limited treatment options. During 2024 significant milestones has been achieved as a positive Phase 2a data showcasing an attractive benefit-risk profile for its lead candidate, successfully securing one of Sweden’s largest biotech raises in 2024, signing a strategic licensing agreement with a partner in Japan and launching a global Phase 2b trial in IPF.”
“It’s been an incredible year for Vicore, and the credit goes to our amazing team. I think what underlies our achievements is an incredible ecosystem in Sweden. We’re very excited now with the capital that we have obtained to advance our lead program into late stage clicinal development for idiophatic pulmonary fibrosis. We’re very excited as a Swedish company to potentially be able to change the lives of patients suffering from this disease as a first place where we play a role and to then go further beyond that, Ahmad Mousa, the CEO of Vicore Pharma said.
This year’s three award finalists were Vicore Pharma, Xbrane Biopharma and Pelago Bioscience. The SwedenBIO Award is given annually in collaboration with HealthCap to a member company that has shown outstanding achievements and contributions to society and that exemplifies the potential of a strong Swedish life-science industry.
“We have supported this award for a number of years, and we will continue to do so, because it is an important factor in making sure we have a strong local network and ecosystem. Life science is a tough industry where success doesn’t come easy, which is why it’s important to celebrate when things turn out the right way. It’s a no brainer for us to sponsor the SwedenBIO award, said Carl Kilander, Partner at HealthCap, who handed out the award onstage at the summit.
The jury consisted of SwedenBIO’s board:
Anders Persson, AstraZeneca
Kerstin Falck, Pfizer
Renée Aguiar-Lucander, Calliditas
Christine Wesström, Sobi
Sara Corin, Cytiva
Mårten Winge, Strike Pharma
Carl Kilander, HealthCap
Sana Alajmovic, Sigrid Therapeutics
Branschorganisationen SwedenBIO arbetar för en konkurrenskraftig life science-sektor i Sverige. Vi gör det genom att skapa effektiva kontaktytor mellan sektorns olika aktörer, genom att bygga kunskap och genom att ge branschen en stark röst i samhällsdebatten. Våra mer än 330 medlemsföretag bedriver verksamhet inom läkemedelsutveckling, bioteknik, medicinteknik och diagnostik eller är experter inom bland annat affärsutveckling, finansiering, immaterialrätt och juridik.
Powered by Notified